Private Wealth Partners LLC Trims Position in Danaher Co. (NYSE:DHR)

Private Wealth Partners LLC lessened its stake in shares of Danaher Co. (NYSE:DHR) by 3.9% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 100,045 shares of the conglomerate’s stock after selling 4,033 shares during the period. Danaher accounts for approximately 1.9% of Private Wealth Partners LLC’s portfolio, making the stock its 18th biggest position. Private Wealth Partners LLC’s holdings in Danaher were worth $24,996,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Cape Investment Advisory Inc. purchased a new stake in Danaher during the fourth quarter worth approximately $25,000. Tsfg LLC grew its holdings in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher during the second quarter valued at $25,000. nVerses Capital LLC acquired a new stake in shares of Danaher during the second quarter valued at $25,000. Finally, Redmont Wealth Advisors LLC purchased a new position in Danaher during the first quarter worth about $30,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other Danaher news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,659 shares of company stock worth $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on DHR shares. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. Jefferies Financial Group initiated coverage on Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 target price on the stock. Barclays boosted their price objective on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Stifel Nicolaus boosted their price objective on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $278.94.

Danaher Stock Down 1.0 %

Shares of DHR opened at $271.98 on Thursday. The firm has a market capitalization of $196.43 billion, a price-to-earnings ratio of 46.10, a PEG ratio of 4.38 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The business’s fifty day moving average price is $263.20 and its two-hundred day moving average price is $256.22. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue was down 2.9% on a year-over-year basis. During the same period last year, the company earned $2.05 EPS. On average, analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.40%. Danaher’s dividend payout ratio is presently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.